GLPwatch
Papers (10386)
Page 139 of 174, ranked by citation count.
- Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
- Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
- Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.
- Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.
- Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
- Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large.
- Injectable drugs for weight management.
- Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
- Semaglutide in weight management - Author's reply.
- Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.
- Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
- Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
- Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.
- Liraglutide modulates adhesion molecules and enhances cell properties in three-dimensional cultures of olfactory ensheathing cells.
- Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.
- Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.
- Effects of tryptophan-selective lipidated glucagon-like peptide 1 (GLP-1) peptides on the GLP-1 receptor.
- [The glucagon-like peptide-1 receptor-agonist semaglutide].
- The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.
- Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.
- Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.
- Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2.
- Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
- "Why you should (not) use semaglutide?": A critical discourse analysis on health professionals' videos of semaglutide for weight loss on Douyin.
- Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
- Sex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States.
- Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).
- Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.
- Semaglutide and Cardiovascular Outcomes.
- A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder.
- Semaglutide in Patients Undergoing Anesthesia for Otolaryngologic Procedures.
- 2017 New Drug Update.
- A review regarding the article 'Semaglutide and heart failure: Updated meta-analysis'.
- A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.
- Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
- Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.
- Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply.
- Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.
- Treatment of obesity in spinal cord injury with tirzepatide: a case report.
- Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.
- The incretin system in the management of type 2 diabetes mellitus.
- After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
- Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
- Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
- GLP-1 and GIP Changes after Sleeve Gastrectomy and Weight Regain in Adolescents. Do we need a Boost?
- Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.
- Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.
- Slimming cardiac adipose tissue with liraglutide: pericardial is not epicardial fat (the LIRAFLAME substudy).
- Unremitting Nausea Due to Lurasidone After Semaglutide Initiation.
- RGB Trichromatic Whiteness Assessment of Bio Analytical Chromatographic Tool Using Fluorescence for Quantitation of Semaglutide: Application to Pharmaceutical Preparations and Spiked Plasma.
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
- Orforglipron in type 2 diabetes mellitus and obesity: an overview.
- Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.
- Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.
- [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
- Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report.
- Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
- Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.
- Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique.